Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCPS | Q96C86 | 3/20 | 0.36 |
| ▸ | TACR1 | P25103 | 2/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | INMT | O95050 | 1/20 | 0.31 |
| ▸ | ACHE | P22303 | 1/20 | 0.31 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14996130 | 1.00 | DCPS (0.36) | DCPSTACR1ABCC1ALDH1A1MAPT | |
| SCHEMBL12465037 | 0.92 | DCPS (0.35) | DCPSABCC1ALDH1A1MAPTINMT | |
| SCHEMBL10183545 | 0.92 | DCPS (0.41) | DCPSABCC1MAPTINMT | |
| SCHEMBL18214643 | 0.89 | DCPS (0.34) | DCPS | |
| SCHEMBL10184144 | 0.89 | DCPS (0.35) | DCPSMAPT | |
| SCHEMBL10171882 | 0.87 | DCPS (0.36) | DCPSTACR1ALDH1A1MAPTINMT | |
| SCHEMBL18214649 | 0.83 | MAPT (0.33) | DCPSABCC1ALDH1A1MAPTINMT | |
| SCHEMBL18697917 | 0.82 | DCPS (0.35) | DCPSTACR1ALDH1A1MAPTINMT | |
| SCHEMBL18697878 | 0.81 | POLRMT (0.30) | — | |
| SCHEMBL10149577 | 0.81 | MAPT (0.38) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3150608-A1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2480552-B1 | 2' -FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2016-11-09 | — | — | EP | disclosed |
| US-8455451-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7973013-B2 | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2011-07-05 | — | — | US | disclosed |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009147-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, NSUN2, CDA | DCPS 173/4885TACR1 4389/4885ABCC1 1088/4885 |
| US-20110070194-A1 | 2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT | PNP, RNGTT, SLC29A1 | DCPS 248/4885TACR1 3549/4885ABCC1 1131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.